The Biosimilars Generation website is an information resource for patients, health care providers and all Canadians about biosimilar medicines in Canada.
Easy to navigate, it offers visitors key information on the science of biosimilars in a reader friendly language, where to connect with others taking or prescribing biosimilars, what provinces are doing to make them available, and the role they play in keeping public and private drug programs affordable, today and into the future.
Sandoz, the pioneer and global leader in biosimilars
Sandoz is committed to increasing patient access to high-quality, life-enhancing biosimilars. It is the pioneer and global leader in biosimilars. In Canada, Sandoz markets two products: Omnitrope® and Erelzi®.
With a leading pipeline, Sandoz plans to launch five biosimilars of major oncology and immunology biologics across key geographies by 2020. This will be enabled by 11 filings over a three-year period (2015-2017). Sandoz’ early-stage pipeline has additional assets in oncology as well as other specialty therapeutic areas with plans to start new programs every year.
As a division of the Novartis Group, Sandoz is well-positioned to lead the biosimilars industry based on its experience and capabilities in development, manufacturing and commercialization.
® : Registered trademark owned or used under license by Sandoz Canada Inc.